Does the 2026 Malaysia ACS guideline meaningfully expand post-ACS cardiometabolic therapy?

Which post-ACS patients should be considered early for an SGLT2 inhibitor?

Consider an SGLT2 inhibitor early after ACS mainly in patients who already have a clear evidence-based indication beyond the ACS itself — especially type 2 diabetes, heart failure (particularly reduced EF), or chronic kidney disease — once they are haemodynamically stable, eating/drinking, and without ketoacidosis or s

Why should semaglutide usually wait until oral intake and haemodynamics are stable after ACS?

Semaglutide is usually deferred immediately after ACS because the early post-ACS phase prioritises drugs that are proven safe and beneficial once the patient is clinically stabilised, while semaglutide is not an acute ACS therapy and commonly causes gastrointestinal effects that can impair nutrition, hydration, and abs

How should SGLT2 inhibitors and semaglutide be sequenced when a post-ACS patient has both CKD or HF and obesity?

In a post-ACS patient who also has CKD or HF plus obesity, the usual sequence is: 1. Start an SGLT2 inhibitor first if the patient is haemodynamically stable and there is a clear HF and/or CKD indication, because SGLT2 inhibitors have the strongest direct evidence and guideline support for heart failure and kidney prot

What evidence gap should be discussed before using semaglutide specifically for post-ACS risk reduction?

The key evidence gap is that semaglutide has not been tested in a dedicated randomized trial started during the early post-ACS period specifically to reduce recurrent ischemic events after ACS. The major semaglutide cardiovascular outcome trials either excluded recent acute coronary/cerebrovascular events or enrolled b

Which renal, volume-status, and sick-day checks should be built into a post-discharge SGLT2 pathway?

A post-discharge SGLT2 inhibitor pathway should usually build in 3 safety domains from day 0: renal function, volume status / diuretic interaction, and sick-day / ketoacidosis prevention. Key practical checks are: confirm baseline creatinine/eGFR, identify patients at higher risk of volume depletion or AKI (especially